In Hong Kong, multiple authorities are responsible for the oversight and regulation of cellular therapy products. The Department of Health serves as the principle advising authority to the government of Hong Kong for developing and executing public health laws and statuatory functions. Additionally, Hong Kong’s Drug Office has the authority to regulate pharmaceutical products including biological products from human origin. At the time of this writing, specific laws, regulations, and guidelines could not be found on the websites belonging to the Department of Health or the Hong Kong Drug Office.
(October 2014)
REGULATORY UPDATE: FDA Releases HCT/P Guidance Documents Related to Donor Eligibility
January 07, 2025
FDA Approves First MSC Therapy to Treat GvHD
January 02, 2025
BioBridge Global Launches BBG Advanced Therapies Subsidiary
January 02, 2025